UAB 1356 - A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotropic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)

Grant

Date/time Interval

  • April 16, 2014 - April 15, 2015
  • Total Award Amount

  • 27335.00
  • Direct Costs

  • 21695.00
  • Sponsor Award Id

  • Contributor

  • Eckhoff M.D., Devin   Investigator  
  • Gray, Stephen   Investigator  
  • White, Jared   Investigator